---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-333813"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2026-08-05T11:02:49+00:00"
generated_at: "2026-08-05T11:06:17.955031+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio Q2 net loss $8.9M; positive bempikibart Phase 2a data; $200M offering

## Summary
- Net loss $8.9M ($0.44/share) vs $9.5M ($0.78) in Q2 2025; R&D expense $4.3M, G&A $4.9M.
- Cash $106.3M at June 30, 2026; combined with $200M July offering funds through Phase 3 topline.
- Bempikibart showed 35.3% mean SALT reduction at Week 36; 40% SALT-20 response (mITT) in SIGNAL-AA Part B.
- Registration-directed program for severe/very severe AA expected to start 1H2027, pending regulatory discussions.
- ADX-914-XL (half-life extended anti-IL-7Rα) advancing in preclinical development.

## SEC filing metadata
- accession: 0001193125-26-333813
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2026-08-05T11:02:49+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312526333813/0001193125-26-333813-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312526333813/qttb-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-333813
- JSON: https://secwatch.observer/filing/0001193125-26-333813.json
- Plain text: https://secwatch.observer/filing/0001193125-26-333813.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.